Numinus builds on strong MAPS Phase 3 trial results through Compassionate Access Trial of MDMA for PTSD
Yesterday, MAPS announced significant, positive results for their Phase 3 clinical trial of MDMA-assisted therapy for PTSD – a major…
Numinus Congratulates MAPS on Phase 3 Clinical Trial of MDMA for severe PTSD
1 in 11 Canadians will suffer from PTSD in their lifetime. We urgently need new approaches to mental health care…
Numinus Wellness’s trial for MDMA-assisted therapy is in pre-implementation stage
The study, which is in collaboration with MAPS Public Benefit Corporation (MAPS PBC), subsidiary of the Multidisciplinary Association for Psychedelic…
Numinus Wellness Acquires Mindspace Wellbeing to Expand into Montreal
Numinus Wellness Inc. will soon have three locations in Montreal thanks to a recent acquisition. The Vancouver-based company announced this…
Company with Nanaimo lab gets federal approval for psychedelic drug research
Numinus’ recently amended Health Canada licence allows the company to produce and extract psilocybin from mushrooms. The Nanaimo News Bulletin…